Gen-Probe, MPI market cancer assays:
This article was originally published in Clinica
Executive Summary
San Diego, California-based Gen-Probe is to collaborate on a non-exclusive basis with Molecular Profiling Institute (MPI) to accelerate commercialisation of Gen-Probe's pipeline of cancer diagnostics. Under the terms of the agreement, of which the financial details were not disclosed, MPI will validate, commercialise and undertake market development activities for up to four Gen-Probe assays. The first of these will be the firm's investigational PCA3 test for prostate cancer. Gen-Probe, which acquired a minority stake in MPI as part of the agreement, will have a five-year right of first refusal should MPI seek a partner to develop non-tissue-based diagnostic products based on cancer and predictive medicine markers discovered or acquired by MPI.